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Abstract 
LncRNAs are novel noncoding RNAs involved in the epigenetic regulation of gene expression by 
recruiting ribonucleoprotein complexes to specific genomic loci to initiate histone methylation and/or other 
chromatin modifications. LncRNAs themselves function as tumor suppressors or oncogenes, depending on 
the gene regulatory networks they govern. We identified lnc00673 (ERRLR01) as a marker of overall survival 
(OS) in breast cancer patients. Specifically, ERRLR01 levels were elevated in triple-negative breast cancer 
(TNBC) as compared to Luminal- A, Luminal-B, and HER2 breast cancer subtypes. ERRLR01 levels were 
also inversely correlated with breast cancer survival across all breast cancer patients. Upon stratification, OS 
   ERα
 
tumors               h   g                          h       ERα+
 
tumors, ERRLR01 correlated with 
positive outcomes. This suggests ERRLR01 is modulated by hormone signaling in breast cancer. Gene-
network analysis revealed ERRLR01 correlated with distinct pathways         g “    h                 ”     
“                        ". These data suggest ERRLR01 could be an oncogene in TNBC, as well as a 
biomarker in breast cancer patients. 
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Introduction 
Long-noncoding RNAs function as decoys, regulators of translation, and/or molecular scaffolds that 
recruit chromatin modifying enzymes to distinct genomic loci1-4. LncRNA transcripts are transcribed in sense 
and/or anti-sense orientation5,6,7, and lncRNA transcription depends upon a tightly controlled regulatory 
network that as of yet, is still not well understood. The ENCODE Consortium determined the abundance and 
location of many lncRNAs across several species, which in various cases are conserved through positional 
synteny8,9. In many cases, lncRNAs reside near protein coding regions and function in cis to maintain the 
surrounding chromatin in an open and epigenetically active state. In other cases, lncRNAs can be 
transcribed in an anti-sense orientation to a protein-coding gene, which in turn recruits histone chromatin-
modifying complexes that support gene silencing10,11. The nomenclature for a particular lncRNA is derived, in 
part, from the closest neighboring protein coding gene. For instance, lincRNA-p21 neighbors CDKN1A, 
regulates CDKN1A (p21) expression, and when lincRNA-p21 is knocked down phenocopies the effects 
imparted by the loss of CDKN1A12,13. Additionally, genes such as ANRIL (antisense noncoding RNA in the 
INK4 locus), which is an antisense transcript produced within the CDKN2B locus, recruits PRC1/2 
complexes and inhibits CDKN2B gene expression14,15. 
There has been a recent effort to elucidate lncRNA function by identifying particular cellular states and/or 
pathophysiologies associated with dysregulated lncRNA expression16. In this context, modulating lncRNA 
abundance, either through gain- or loss-of-function approaches serves as an opportunity to understand 
which gene-regulatory networks a specific lncRNA is associated with. Furthermore, alteration of lncRNA 
expression that in turn promotes changes in cellular phenotypes indicates a particular lncRNA could be a 
driver of a disease or pathophysiological state. Several lncRNAs have been identified as important mediators 
of disease states, such as PTCSC3 in papillary thyroid carcinoma, and ANRIL in type-2 diabetes17,18. 
Additionally, MALAT-1 is expressed in the heart, lung, and kidneys, but is elevated in lung tumor tissue and 
has elevated biological activity in metastatic lung adenocarcinoma as compared to a benign or pre-malignant 
state19-22. HOTAIR, initially described in fibroblasts, regulates the cluster of HOX genes through cis as well 
as trans-regulatory mechanisms16, and is associated with oncogenesis. HOTAIR expression levels are high 
in several tumors types including lung, breast, and prostate. Furthermore, ectopic expression of HOTAIR 
results in aberrant PRC2 function and improper recruitment of PRC2-associted complexes to the correct 
genomic loci. This process facilitates promiscuous gene regulation allowing for a pro-tumorigenic state23. 
Several other lncRNAs including PCAT-1 and GAS5 also have tumorigenic function; however, there is a 
growing need to elucidate the function of the nearly 118,000 recently annotated human lncRNAs. Given 
lncRNAs serve as decoys, function as scaffolds that mediate protein-protein interactions, and promote 
chromatin remodeling through recruitment of DNA- modifying enzymes to distinct genomic loci, the capability 
to tease out specific mechanisms associated with a particular lncRNA remains a challenge. However, 
determining putative lncRNA functions can be initiated through investigation of associative miRNA and 
mRNA gene regulatory networks, which could then be utilized to determine if a lncRNA harbors putative 
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oncogenic potential when dysregulated. 
In this study, we identified ERRLR01, as a lncRNA whose expression was differentially abundant across 
four breast cancer subtypes within Affymetrix and The Cancer Genome Atlas (TCGA) datasets. Furthermore, 
ERRLR01 expression correlated with overall survival (OS) and relapse-free survival (RFS) outcomes within 
an Affymetrix dataset. Previous reports indicated ERRLR01 was a prognostic marker in non-small cell lung 
cancer24, and functioned as a pro- metastatic lncRNA in melanoma25. In our model, ERRLR01 was 
aberrantly expressed across breast cancer tumor subtypes and cell lines. Therefore, we performed gene 
network analysis and identified a series of pathways highly correlated with ERRLR01 expression, and further 
recognized putative miRNA-lncRNA interactions that could be responsible for modulating ERRLR01 
expression in specific cellular contexts. Overall, these studies indicate ERRLR01 may function as an 
oncogene in breast cancer, and that anti-sense strategies developed to target this lncRNA may eventually 
become a new therapeutic approach to treat breast cancer patients. 
Materials and Methods:  
Gene chip database construction 
To develop survival analysis software, a gene chip database was firs established as described 
previously26. In brief, a GEO search was made to identify breast cancer gene expression datasets with 
available survival data, with each dataset containing at least 30 patient samples. The raw .CEL files were 
downloaded and MAS5 normalized in the R statistical environment (http://www.r-project.org) using the Affy 
Bioconductor library. Database quality control and removal of duplicate samples were performed as 
described27. This analysis methodology was then utilized on a curated Affymetrix dataset described in 
Gyorffy, B et. al., 201339. Patient samples from the Affymetrix datasets were primarily of Caucasian origin, 
and biopsies were obtained from the primary breast tumor. This curated dataset contains over 2000 breast 
                                     g                             j          h              ERα+39. 
Specifically, Affymetrix dataset analysis was performed whereby expression of ERRLR01 in each patient 
sample was determined using probe set 227452_. The original signal was MAS5 normalized, and listed in 
rank-order via spearman rank analysis38,39. For ERRLR01, the probe set 227452_at was used. This probe 
set has a specificity of one ERRLR01 transcript and a coverage of 100% of the transcript variants of 
ERRLR0128. ESR1 and HER2 status was determined for each sample using the probe sets 205225_at and 
216836_s_at as described earlier29. To determine receptor status, the raw expression cutoff values of 500 
and 1,150 were used for ESR1 and HER2, respectively. 
RNA-Seq database construction 
RNA-Seq measurement for breast cancer patients30
 
were published by The Cancer Genome Atlas 
(TCGA) of the National Cancer Institute (https://cancergenome.nih.gov/) and we downloaded the pre-
processed level 3 data generated using the Illumina HiSeq 2000 RNA Sequencing Version 2 platform. The 
primary tumor samples from this dataset were obtained from patients of Caucasian origin. For these 
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samples, expression levels were determined using a combination of MapSplice and RSEM. We have 
combined the individual patient files in R using the plyr package. TCGA datasets also underwent Kaplan-
Meir survival analysis utilizing the statistical methodologies highlighted below. 
Quantitative Real Time PCR 
For qPCR, cells were lysed in TRIzol (Life Technologies), and total RNA was used as the input for 
subsequent RT-PCR reactions. For lncRNA analysis, cDNA synthesis and qRT-PCR were performed 
according to the miScript II RT Kit (Qiagen) and miScript SYBR® Green PCR Kit (Qiagen) protocols 
respectively31. MiRNA levels were normalized to RNU6B levels. For mRNA analysis, cDNA synthesis and 
qRT-PCR were performed per the RT2
 
First Strand Kit and RT2
 
qPCR Primer assay protocols from Qiagen. 
Genetic-Network and Go Term Analysis 
For gene pathways analysis, Spearman-Rank analysis was performed on the entire Affymetrix data. We 
identified the top 200 genes most highly correlated with ERRLR01 across all patient specimens. The top 200 
genes are equivalent to roughly the top 5% of genes in the Spearman- Rank analysis. We utilized this gene 
set to perform GO term analysis using the WebGestalt algorithm55. In these studies, we performed a series 
of data queries including GO term analysis, KEGG analysis, and miRNA target analysis. The algorithm 
compares the enrichment of genes uploaded in the program compared to reference gene names of the 
entire human genome. Utilizing hypergeometric analysis with Benjamini and Hochberg multiple test 
adjustment (i.e., FDR Analysis), we identified significant gene pathways using a cutoff of p value < 0.05. 
Only pathways containing 6 genes or more from the genes loaded into the algorithm were analyzed. 
Spearman-Rank analysis was also utilized to identify genes that were the most anti-correlated with 
ERRLR01. Similar statistical analysis was performed, and the resulting data is highlighted in the 
supplemental data. 
Statistical analysis 
Molecular subtypes were designated per the StGallen guidelines using expression of ESR1, HER2, and 
MKI67 (PMID: 23917950). This includes a TNBC cohort (ESR1 and HER2 negative patients), a HER2-
enriched cohort (HER2 positive and ESR1 negative patients), a Luminal A cohort (ESR1 positive HER2 
negative with low MKI67), and a Luminal B cohort (ESR1 positive and HER2 positive as well as ESR1 
positive HER2 negative with high MKI67 expression). 
Survival analysis was performed in the R statistical environment (http://www.r-project.org) using the 
survival Bioconductor library. For the expression of ERRLR01, each percentile (of expression) between the 
lower and upper quartiles was computed and the best performing threshold was used as the final cutoff in 
the Cox regression analysis. Kaplan–Meier survival plot, and the hazard ratio with 95% confidence intervals 
and log-rank P value were calculated and plotted in R. Kruskal-Wallis test was used to compare continuous 
expression among multiple cohorts and Mann-Whitney test was used to compare two cohorts. Statistical 
significance was set at p<0.05. 
Results 
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ERRLR01 is Highly Expressed in Estrogen Receptor Negative Tumor Subtypes 
We performed an in-silico screen of lncRNAs that were differentially expressed across breast cancer 
patients, or between normal and breast cancer tissue samples. We identified ERRLR01 as a long noncoding 
RNA expressed at higher levels in breast cancer patient samples as compared to normal breast tissue. We 
utilized numerous databases including MiTranscriptome32, which is a meta-assembly of 6,503 RNA-Seq 
libraries (Figure S1). ERRLR01 is a recently described lncRNA that has sequence similarity to the steroid 
receptor RNA activator 1, and hence termed ERRLR01 (SRA-like-non-coding RNA). ERRLR01 is located on 
chromosome 17q24.3, a region associated with genomic breakpoints within a variety of cancer types 
including breast, lung, colorectal, and uterine leiomyomas33-37. Additionally, ERRLR01 was identified to play 
a role in melanoma invasion25, and was linked with worse overall survival in melanoma patients. ERRLR01 
expression was also previously reported to be elevated in melanoma cell lines post invasion, suggesting 
ERRLR01 promotes invasion. Given the role of ERRLR01 in melanoma, and the finding that ERRLR01 was 
elevated in breast cancer specimens as compared to normal breast tissue, we decided to investigate 
whether ERRLR01 could serve as a biomarker for breast cancer progression and/or disease onset. 
ERRLR01 is a Predictor of Overall Survival in Breast Cancer 
We analyzed Affymetrix U133 gene chip data, as well as the breast cancer TCGA dataset and 
determined that across four distinct breast cancer subtypes, as determined by PAM50 classification, that 
ERRLR01 was elevated in TNBC patient samples (Figure 1). The analysis of the Affymetrix dataset was 
performed by Spearman rank analysis whereby expression of ERRLR01 in each patient sample was 
determined by probe set 227452_ and whereby the signal 
was MAS5 normalized, and listed in rank-order38,39. The average rank-order across all patients within the 
sample subset was determined and plotted as a box-whisker-plot (Figure 1a). ERRLR01 expression was 
elevated in both TNBC as well as HER2+
 
patient subtypes when compared to Luminal-A and Luminal-B 
subtypes. This indicated ERRLR01                             h ERα           b                          
validate this result, we assessed the expression of ERRLR01 in the breast cancer TCGA dataset30. Here, 
ERRLR01 expression was determined using the MapSplice Algorithm40, and the resultant log(2) transformed 
normalized data was plotted as a box-whisker-plot (Figure 1b). In this dataset ERRLR01 expression was 
elevated in both TNBC and HER2 positive patient samples. Together, results from both patient datasets 
indicated that ERRLR01  x                         ERα
 
        b                      ERα+
 
tumor 
subtypes (p value < 1  1016, as determined by Kruskal-Wallis analysis). 
This analysis indicated that ERRLR01 may be inversely correlated with hormone signaling, as hormone-
sensitive tumors expressed lower levels of ERRLR01 than those with hormone- independent tumors. To test 
this hypothesis Kaplan-Meir survival analysis was performed, coupled with Cox regression analysis on the 
Affymetrix dataset described above. We determined that within all breast cancer patient samples, high 
ERRLR01 expression inversely correlated with RFS (Figure 2a); HR = 1.5 with a p value < 5  106. When 
  g  g    g          b  ERα                   h   ERα+
 
patients with high expression of ERRLR01 had 
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better overall survival (OS) rates than those with low ERRLR01 expression (Figure 2c); HR = 0.75 with a p 
value < 0.0046. We did not perform RFS analysis after patient stratification due to smaller sample size and 
                           I         g                   h ERα
 
tumors, ERRLR01 expression was inversely 
correlated with OS (Figure 2b); HR = 1.31 with a p value < 0.095. This was a unique finding and suggests 
ERRLR01 is regulated b  ERα     h   ERα   g     g          ERRLR01 expression. 
To test this notion further, we assessed ERRLR01–related OS in breast cancer patients after PAM50 
sub-stratification. Within Basal-like (i.e., TNBC) and HER2-positive breast cancer categories high ERRLR01 
expression inversely correlated with OS, while in Luminal-A and Luminal-B categories ERRLR01 expression 
correlated with OS (Figure S2). We attempted to validate this survival relationship with ERRLR01 using the 
TCGA datasets, however, we did not find any significant survival benefit based on differential ERRLR01 
expression. It should be noted that survival data in TCGA is harder to determine, given a majority of samples 
were acquired from primary tumor samples, with only 5--10yr follow-up. 
Characterization of the ERRLR01 Locus and Interacting Transcription Factors 
Given the significant ERRLR01-related OS between hormone-dependent and hormone- independent 
breast cancer patients, we wanted to elucidate a putative mechanism for such a relationship. To do this we 
first determined the genomic location of ERRLR01 and inquired as to which putative regulatory moieties 
could serve as signals to recruit potential RNA and protein binding components to the ERRLR01 transcript. 
ERRLR01 is positionally conserved via synteny between the human and mouse genome (Figure 3a). A 
moderate level of transcription was observed from both RNA-Seq data on 9 cell lines from ENCODE, and 
from lncRNA RNA-Seq datasets where ERRLR01 was expressed highest in testes and brain tissue, but 
lower in normal breast and other tissues. Furthermore, evidence of CpG promoter methylation was observed 
(Methylation Score = 117) using the UCSC genome browser dataset. Overall these data support the notion 
that ERRLR01 is expressed at low to moderate levels in most normal tissue specimens or cell lines. These 
findings are also in line with the Affymetrix and TCGA datasets, where the raw FPKMs for ERRLR01 were 
10 or less. 
Upon further characterization of the ERRLR01 genomic loci we identified H3K4Me1 and H3K4Me3 
marks between ERRLR01 exons three and four, and in some cases overlapped with CTCF binding sites, as 
well as other transcription factors (Figure 3b). The convergence of CTCF binding on the ERRLR01 genomic 
loci was of particular interest since CTCF is a well- documented 17b-estradiol regulated protein whose 
function is that of an insulator to prevent enhancer element binding to particular promoters41-47. As an 
example, CTCF is a factor known to be regulated by ERα in MCF-7 cells, and therefore could also affect 
ERRLR01 levels in these estrogen-responsive cell lines. This notion is supported by GEO datasets, (see 
Figure S3). Therefore, ERRLR01 could operate as an oncogene as is suggested by some groups, yet in 
hormone-sensitive tumors a 17b estradiol-CTCF regulatory axis could be reducing the activity of ERRLR01. 
I              h              h    ERα b     g                           h  3’         h  ERRLR01 transcript. 
Whether these sites are functional or serve as co-activator versus co- repressor binding sites is unclear. 
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Further in silico analysis indicated that the family of GATA transcription factors (including GATA3) also 
bound to the exonic regions of ERRLR01 (Figure 3b). Further work is required to determine the functionality 
of these sites. 
Potential RNA- and miRNA- Binding Sites within the ERRLR01 Locus 
To further understand the potential RNA-regulatory network that ERRLR01 is a part of, we utilized 
several databases to interrogate whether certain RNA-binding proteins interacted with 
ERRLR01, or whether specific miRNAs could bind the ERRLR01 transcript. The strongest RNA binding 
protein interaction we identified was FUS (Figure 4). FUS binding to ERRLR01 was confirmed through the 
StarBase 2.0 algorithm45
 
and is denoted as a HHF3_128133 binding site (Figure 4a). Other RNA binding 
protein sites were identified through HITS-CLIP data; however, a majority of these sites require confirmation 
through RNA-IP experiments before concluding these interactions are relevant. It was interesting to note that 
DGCR8 bound to intronic regions of ERRLR01 indicating that a miRNA sequence may be derived from this 
host sequence. 
Next we asked whether there were any regulatory interactions between miRNAs and the ERRLR01 
transcript. Using the miRdB algorithm46
 
we observed several putative miRNA interactions across ERRLR01, 
and highlighted the top 5 miRNA candidates (Figure 4b). Many of these miRNAs have unknown functions, 
however miR-515 is a well-studied oncogene in breast cancer47-50, and is involved in mediating or regulating 
EMT51-53. miR-515 is also an estrogen regulated gene48   h    ERα     b     h                R-515 and 
regulate gene expression in a 17b-estradiol-dependent manner. 
Overall these bioinformatic analyses indicated that ERRLR01 was a highly regulated lncRNA predictive 
of overall survival in breast cancer patients, and could be regulated by 17b-estradiol signaling in breast 
cancer. To test this notion, we screened for ERRLR01 expression across several breast cancer cell lines. 
We confirmed that several TNBC cell lines harbored high expression of ERRLR01                ERα+ cell 
lines, and normal HMECs (Figure 5). The high expression of ERRLR01 in TNBC cell lines indicates that 
ERRLR01 may be repressed by 17b-estradiol signaling. However, this analysis was done under steady state 
growth conditions whereby 17b-estradiol as present in the growth media. However, a recent study by Lin et 
al.54, indicated that in MCF-7 cells, ERRLR01 levels are low under hormone-depleted conditions yet upon 
17b-estradiol addition ERRLR01 levels increase within 3hrs (Figure S3). The consequences of this rise in 
ERRLR01 levels requires elucidation, as numerous transcription factors and RNA binding proteins may be 
modulated by this change in ERRLR01 levels. It would be interesting to determine in follow-up studies 
whether direct modulation of ERRLR01 induces functional and/or phenotypic consequences in breast cancer 
cells. 
Gene Regulatory Network Analysis Associated with ERRLR01 Expression 
Given the evidence for ERRLR01 to be an estrogen-regulated gene in breast cancer, we wanted to 
identify signaling pathways that may be part of an ERRLR01-mediated RNA network. To do this we 
employed GO term analysis using the WebGestalt algorithm55. We extracted the 
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gene expression profiles from all patients within the Affymetrix dataset and performed Spearman-Rank 
analysis to determine which genes were most correlated with ERRLR01 expression (Figure 6). We used as 
a cut-off the 200 most positively correlated ERRLR01 genes, which is approximately the top 5% genes 
derived from the analysis. We then performed a series of GO term and KEGG analysis using WebGestalt 
against the entire human reference genome, and found significantly enriched ERRLR01 pathways (Figure 
6a). We identified pathways such as Wnt Receptor Signaling (p<7.70  102), Epithelial Differentiation (p<7.7 
 102), and Epithelial Development (p<7.70  102). Importantly, pathways such as Epithelial Development 
and Hormone Signaling were recurring pathways associated with ERRLR01-correlated genes. Therefore, we 
conclude that ERRLR01 is a lncRNA tightly regulated and serves to control proper developmental timing of 
mammary gland differentiation and development. 
Similar analysis was performed on the 200 most inversely correlated ERRLR01-associated genes 
(Figure 6b). Pathways such as Small Molecule Metabolic Processes (p<8.80  103), Cellular Lipid 
Metabolic Processes (p<8.80  103), and Reproductive System Development (p<3.12  102) were 
identified. Similar analysis was performed on the TCGA dataset (see Figures S4-S5). 
Discussion 
ERRLR01 is located on chr17:70,396,217-70,590,488, and was first identified by Schmidt et al., where 
ERRLR01 transcriptionally upregulated MMP9 in in melanoma cell lines25. In this study, ERRLR01 was 
compared across 150 clinical samples from TCGA and found to be elevated in tumors with greater 
thickness. Furthermore, patient samples that were greater than 14.1 RPKM had a worse OS outcome than 
patients with less than 14.1 RPKM. This indicated that ERRLR01 operated as an oncogene in melanoma. 
ERRLR01 was described as an oncogene in other cancer models as well, including lung and pancreatic 
cancer24,56. In lung cancer ERRLR01 expression associated with higher TMN stages as well as lymph node 
metastasis. ERRLR01 also functioned as a pro-metastatic factor in melanoma, since siRNA knockdown 
studies indicate that loss of ERRLR01 resulted in reduced invasion as measured by Boyden-Chamber 
Matrigel assays25. In pancreatic cancer, the direct evidence for ERRLR01 as an oncogene is less well 
determined, as a particular pancreatic cancer risk variant was identified within the ERRLR01 transcript that 
generated a miR-1231 binding site, which presumably supports oncogenesis. More specifically, ERRLR01 
modulated PTPN11 degradation by promoting E3 ligase induced ubiquitination of PTPN11 and diminished 
ERK oncogenic signaling. Therefore, in pancreatic cancer the presumption is that ERRLR01 operates as a 
tumor suppressor by dampening the pro-proliferative MAPK/ERK signaling pathway. 
ERRLR01 could also be a potential therapeutic target given knockdown of ERRLR01 in lung cancer cell 
lines and in mouse xenograft models resulted in reduced cell viability, and reduced cellular growth in vivo. 
ERRLR01 does this by binding directly to LSD1 (KDM1A) and functions as a chaperone protein to recruit this 
histone demethylase to NCALD24. LSD1 is known to regulate cellular differentiation and cell cycle 
progression, while NCALD is a visinin-like protein 1 sub family of EF-hand calcium-binding proteins that is 
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downregulated in patients with poor prognosis tumors and those harboring poorly differentiated ovarian 
tumors57. Therefore, the mechanism of action is such that ERRLR01 recruits LSD1 to epigenetically silence 
NCALD to promote tumorigenesis. The mechanism of action in melanoma is slightly different given 
ERRLR01 serves as a scaffold to bring two protein components in proximity to each other, Brn3a and AR. 
The interaction with ERRLR01 allows these protein heterodimers to bind to specific chromatin regions, within 
a site located in the promoter of MMP925. The transcriptional upregulation of MMP9 imparted by ERRLR01 
promotes a metastatic phenotype in melanoma cell lines. Overall, these studies highlight the notion that 
ERRLR01 mediates oncogenic or tumor suppressor functions dependent upon the cellular context, which is 
true for many non-coding RNAs. 
While ERRLR01 is described as a chaperone protein, our bioinformatics analysis identified ERRLR01 as 
part of a gene-regulatory network involving miRNA sponging and interactions with specific RNA-binding 
proteins. This was an important analysis given the biological significance of both small and long noncoding 
RNAs are becoming increasingly appreciated. We further identified several SNPs across the ERRLR01 
transcript, however it was unclear as to whether any of these polymorphisms were associated with disease 
risk and/or onset. We intend on pursuing this line of analysis given genome-wide association studies 
(GWAS) have identified cancer risk loci outside protein-coding regions, such as PTCSC3 in papillary thyroid 
carcinoma, and ANRIL in type-2 diabetes17,58,59. 
A major finding of this study was that 17b-estradiol regulated ERRLR01 expression. A few studies have 
identified specific lncRNAs to be regulated by 17b-estradiol. For instance, linc00160 expression can be 
modulated by 17b-estradiol, however the mechanism of action is unclear60. Similarly, well-studied lncRNAs 
have been identified to be regulated by 17b-estradiol, including H19, HOTAIR, and MALAT-161-63. In these 
studies, it is unclear how these lncRNAs relate to survival in breast cancer patients, and furthermore, if these 
lncRNAs are associated    h ERα-stratified overall survival. In this study, we provide strong evidence that 
ERRLR01 is prognostic in breast cancer, that ERRLR01–        O                    ERα              h   
ERRLR01             g       b  ERα   g     g    1 b-estradiol-associated coregulatory proteins in breast 
cancer. Overall, the continued efforts to understand this epigenetic regulation mediated by lncRNAs in the 
context of cancer development will aid in the generation of more effective therapeutic strategies to treat the 
disease64. 
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Figure 1: LncRNA expression in breast cancer patient populations which was acquired using an Affymetrix 
U133A array dataset, and is depicted by box-whisker-plots. In this analysis, ERRLR01 expression was 
stratified into 4 subpopulations, and the mean rank expression was reported (panel A). 1 = TNBC, n = 577; 
2 = Luminal A, n = 1432; 3 = Luminal B, n = 632; 4 = HER2+, n = 301. ERRLR01 expression in the TCGA 
dataset (panel B), and data is presented in a log(2) transformed format. 1 = TNBC, n = 154; 2 = Luminal A, 
n = 91; 3 = Luminal B, n = 538; 4 = HER2+, n = 53. *denotes significance at p<1  1016
 
as determined by 
Kruskal-Wallis one-way variance analysis testing. 
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Figure 2: Kaplan-Meir and cox regression analysis of ERRLR01 levels and OS in breast cancer patients. 
Data was obtained from Affymetrix datasets, and analyzed on KM-Plotter software. Panel (A) represents 
RFS in all breast cancer patients, (B) depicts OS in ER-negative breast cancer patients, and panel (C) 
depicts OS in ER-positive breast cancer patients. Hazard ratios and log- rank p values are reported for each 
analysis. ERRLR01               h                           “            ”            “ER-  g              ”  
while positively correlates with OS in “ER-                  ”  
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Figure 3: Genomic analysis of the ERRLR01 gene region and the regulatory factors that interact with 
ERRLR01     g  h   C C        b                                                     gh  (5’    )         
(3’    )  (A) ERRLR01.1 is a 4-exon gene conserved between mouse and human, and is expressed at high 
levels in testis, placenta, and brain tissue. (B, Top Panel) Detectable transcription is present across a panel 
of cell lines with evidence of H3K4Me1 modification. (B, Bottom Panel) Potential estrogen-regulated 
transcription factor binding locations are denoted, such as the GATA family of transcription factors, CTCF, 
    ERα         
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Figure 4: (A) In silico assessment of RNA binding proteins that interact with ERRLR01 as determined by 
HITS-CLIP experiments. StarBase 2.0 was utilized to confirm FUS binding to the ERRLR01 locus. The 
ERRLR01                            h  3’    5’                               b       h      -sense orientation 
(minus strand of the DNA). 
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Figure 5: Quantitative PCR analysis of ERRLR01 expression across a panel of breast cancer cell lines. 
Analysis indicates a few TNBC cell lines express high levels of ERRLR01, as compared to normal HMEC 
lines, as well as ERα+
 
cell lines. 
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Figure 6: Go Term analysis of the top 200 positively correlated ERRLR01 genes via spearman rank analysis 
of the Affymetrix dataset (HGU133). (Panel A) Analysis was performed in Basal-like breast tumors(n = 577), 
given ERRLR01 expression is high / detectable within those samples. Analysis indicated ERRLR01 levels 
              h “C       N                         ”  “     C                   ”  “                    
        ”      “         R g           C                 ”  (Panel B) Go Term Analysis of the top 200 
negatively correlated ERRLR01 genes via spearman rank analysis. Red Boxes highlight significant pathways 
and Black Boxes are highlighted as non-significant pathways. 
D
ow
nl
oa
de
d 
by
 [A
us
tra
lia
n C
ath
oli
c U
niv
ers
ity
] a
t 0
5:4
6 1
2 A
ug
us
t 2
01
7 
